Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
Challenges include side effects, lack of insurance coverage for off-label conditions and high out-of-pocket costs
What People on Reddit Are Saying About Semaglutide TLDR: This individual initially had success with Ozempic, experiencing reduced appetite and weight loss at a lower dosage
However, while Semaglutide has helped many people achieve significant weight loss, some individuals may struggle to see the results they expect
The American Journal of Medicine, 124 (1), 85.e1-85.e8
US$ 22.16
US$ 24.53
US$ 27.33
US$ 24.35
US$ 21.20
